The Secret Life of Viral Entry Glycoproteins: Moonlighting in Immune Evasion

PLoS Pathogens

Volumn 9, Issue 5, 2013, Pages

  Cook, Jonathan D ^a   Lee, Jeffrey E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTEGRIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ARTICLE; EBOLA VIRUS; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING;

ANIMALS; CELL MEMBRANE; EBOLAVIRUS; GLYCOPROTEINS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNE EVASION; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EID: 84878483268     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003258     Document Type: Article

References (53)

1. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, et al. (2004) Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 78: 10370-10377.
2. Qiu X, Audet J, Wong G, Pillet S, Bello A, et al. (2012) Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 4: 138ra181.
3. White JM, Delos SE, Brecher M, Schornberg K, (2008) Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol 43: 189-219.
4. Jeffers SA, Sanders DA, Sanchez A, (2002) Covalent modifications of the Ebola virus glycoprotein. J Virol 76: 12463-12472.
5. Ritchie G, Harvey DJ, Stroeher U, Feldmann F, Feldmann H, et al. (2010) Identification of N-glycans from Ebola virus glycoproteins by matrix-assisted laser desorption/ionisation time-of-flight and negative ion electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom 24: 571-585.
6. Wilson JA, Hevey M, Bakken R, Guest S, Bray M, et al. (2000) Epitopes involved in antibody-mediated protection from Ebola virus. Science 287: 1664-1666.
7. Pantophlet R, Burton DR, (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24: 739-769.
8. Ou W, Delisle J, Jacques J, Shih J, Price G, et al. (2012) Induction of Ebola virus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain. Virol J 9: 32.
9. Dias JM, Kuehne AI, Abelson DM, Bale S, Wong AC, et al. (2011) A shared structural solution for neutralizing Ebola viruses. Nat Struct Mol Biol 18: 1424-1427.
10. Simmons G, Wool-Lewis RJ, Baribaud F, Netter RC, Bates P, (2002) Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol 76: 2518-2528.
11. Reynard O, Borowiak M, Volchkova VA, Delpeut S, Mateo M, et al. (2009) Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J Virol 83: 9596-9601.
12. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, et al. (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454: 177-182.
13. Francica JR, Varela-Rohena A, Medvec A, Plesa G, Riley JL, et al. (2010) Steric shielding of surface epitopes and impaired immune recognition induced by the Ebola virus glycoprotein. PLoS Pathog 6: e1001098 doi:10.1371/journal.ppat.1001098.
14. Sanchez A, Yang ZY, Xu L, Nabel GJ, Crews T, et al. (1998) Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol 72: 6442-6447.
15. Dolnik O, Volchkova V, Garten W, Carbonnelle C, Becker S, et al. (2004) Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J 23: 2175-2184.
16. Ito H, Watanabe S, Takada A, Kawaoka Y, (2001) Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol 75: 1576-1580.
17. Druar C, Saini SS, Cossitt MA, Yu F, Qiu X, et al. (2005) Analysis of the expressed heavy chain variable-region genes of Macaca fascicularis and isolation of monoclonal antibodies specific for the Ebola virus' soluble glycoprotein. Immunogenetics 57: 730-738.
18. Maruyama T, Parren PW, Sanchez A, Rensink I, Rodriguez LL, et al. (1999) Recombinant human monoclonal antibodies to Ebola virus. J Infect Dis 179 Suppl 1: S235-239.
19. Cianciolo GJ, Copeland TD, Oroszlan S, Snyderman R, (1985) Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science 230: 453-455.
20. Morozov VA, Morozov AV, Semaan M, Denner J, (2012) Single mutations in the transmembrane envelope protein abrogate the immunosuppressive property of HIV-1. Retrovirology 9: 67.
21. Yaddanapudi K, Palacios G, Towner JS, Chen I, Sariol CA, et al. (2006) Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J 20: 2519-2530.
22. Mangeney M, Heidmann T, (1998) Tumor cells expressing a retroviral envelope escape immune rejection in vivo. Proc Natl Acad Sci U S A 95: 14920-14925.
23. Mangeney M, Renard M, Schlecht-Louf G, Bouallaga I, Heidmann O, et al. (2007) Placental syncytins: genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins. Proc Natl Acad Sci U S A 104: 20534-20539.
24. Dupressoir A, Lavialle C, Heidmann T, (2012) From ancestral infectious retroviruses to bona fide cellular genes: role of the captured syncytins in placentation. Placenta 33: 663-671.
25. Moldenhauer G, Henne C, Karhausen J, Moller P, (1999) Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments. Immunology 96: 473-484.
26. Cresswell P, (1994) Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 12: 259-293.
27. Basha G, Omilusik K, Chavez-Steenbock A, Reinicke AT, Lack N, et al. (2012) A CD74-dependent MHC class I endolysosomal cross-presentation pathway. Nat Immunol 13: 237-245.
28. Zhou C, Lu L, Tan S, Jiang S, Chen YH, (2011) HIV-1 glycoprotein 41 ectodomain induces activation of the CD74 protein-mediated extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to enhance viral infection. J Biol Chem 286: 44869-44877.
29. Chang TL, Gordon CJ, Roscic-Mrkic B, Power C, Proudfoot AE, et al. (2002) Interaction of the CC-chemokine RANTES with glycosaminoglycans activates a p44/p42 mitogen-activated protein kinase-dependent signaling pathway and enhances human immunodeficiency virus type 1 infectivity. J Virol 76: 2245-2254.
30. Dunn SJ, Khan IH, Chan UA, Scearce RL, Melara CL, et al. (2004) Identification of cell surface targets for HIV-1 therapeutics using genetic screens. Virology 321: 260-273.
31. Neil SJ, Zang T, Bieniasz PD, (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425-430.
32. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P, (2009) Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A 106: 2886-2891.
33. Lau D, Kwan W, Guatelli J, (2011) Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens. J Virol 85: 9834-9846.
34. Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, et al. (2010) Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol 84: 7243-7255.
35. Lopez LA, Yang SJ, Exline CM, Rengarajan S, Haworth KG, et al. (2012) Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts. J Virol 86: 5467-5480.
36. Skasko M, Wang Y, Tian Y, Tokarev A, Munguia J, et al. (2012) HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions. J Biol Chem 287: 58-67.
37. Branco LM, Grove JN, Moses LM, Goba A, Fullah M, et al. (2010) Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects. Virol J 7: 306.
38. Branco LM, Garry RF, (2009) Characterization of the Lassa virus GP1 ectodomain shedding: implications for improved diagnostic platforms. Virol J 6: 147.
39. Chiang SF, Lin TY, Chow KC, Chiou SH, (2010) SARS spike protein induces phenotypic conversion of human B cells to macrophage-like cells. Mol Immunol 47: 2575-2586.
40. Kong L, Giang E, Robbins JB, Stanfield RL, Burton DR, et al. (2012) Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci U S A 109: 9499-9504.
41. Helle F, Vieyres G, Elkrief L, Popescu CI, Wychowski C, et al. (2010) Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol 84: 11905-11915.
42. Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, et al. (2002) Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 195: 35-41.
43. Machiels B, Lété C, Guillaume A, Mast J, Stevenson PG, et al. (2011) Antibody evasion by a gammaherpesvirus O-glycan shield. PLoS Pathog 7: e1002387 doi:10.1371/journal.ppat.1002387.
44. Ressing ME, van Leeuwen D, Verreck FA, Keating S, Gomez R, et al. (2005) Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. J Virol 79: 841-852.
45. Wei CJ, Boyington JC, Dai K, Houser KV, Pearce MB, et al. (2010) Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med 2: 24ra21.
46. Das SR, Puigbò P, Hensley SE, Hurt DE, Bennink JR, et al. (2010) Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain. PLoS Pathog 6: e1001211 doi:10.1371/journal.ppat.1001211.
47. Bukreyev A, Yang L, Fricke J, Cheng L, Ward JM, et al. (2008) The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 82: 12191-12204.
48. Aguilar HC, Matreyek KA, Filone CM, Hashimi ST, Levroney EL, et al. (2006) N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J Virol 80: 4878-4889.
49. Moore JP, Sodroski J, (1996) Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 70: 1863-1872.
50. Schlecht-Louf G, Renard M, Mangeney M, Letzelter C, Richaud A, et al. (2010) Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. Proc Natl Acad Sci U S A 107: 3782-3787.
51. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336-343.
52. Cohen T, Cohen SJ, Antonovsky N, Cohen IR, Shai Y, (2010) HIV-1 gp41 and TCRα trans-membrane domains share a motif exploited by the HIV virus to modulate T-cell proliferation. PLoS Pathog 6: e1001085 doi:10.1371/journal.ppat.1001085.
53. Ashkenazi A, Faingold O, Kaushansky N, Ben-Nun A, Shai Y, (2013) A highly conserved sequence associated with the HIV gp41 loop region is an immunomodulator of antigen-specific T cells in mice. Blood 121: 2244-2252.